Patient-reported experience of the impact and burden of neuroendocrine tumors: Oceania patient results from a large global survey.

Published

Journal Article

AIM: Despite the considerable impact of neuroendocrine tumors (NETs) on patients' lives, the patient journey is not well documented. The aim of this survey was to identify the impact and burden of NETs from the patient perspective. METHODS: This was a self-reported global survey regarding NET knowledge/awareness, disease impact/management, interaction with medical teams, and desired improvements. One hundred thirty-eight patients (7% of the global study) in the Oceania region answered closed-ended questions using graded descriptors on their experience of living with NETs. RESULTS: The personal lives of patients were negatively impacted by NETs, including overall energy levels (72%, 99/138), emotional health (66%, 91/138), and finances (56%, 77/138). Eighty-one percent (22/27) of patients not currently working stated that their NET was the reason they were not employed. Of those still working, taking days off work (64%, 39/61), working reduced hours (44%, 27/61) and stopping work for a period of time (31%, 19/61) were the most frequently reported outcomes of having a NET. Although most patients felt supported by their medical team (53% [73/138] reported being extremely or very supported by healthcare professionals in general), patients also identified areas for improvement in patient care. Better access to NET-specific treatments (58%, 80/138), more awareness about NETs (58%, 80/138) and materials to help patients better explain their condition (52%, 72/138) were indicated by patients as ways to help them live better with their disease. CONCLUSION: The survey demonstrated a considerable burden of NETs on patients' lives and identified areas for improvements in long-term management.

Full Text

Duke Authors

Cited Authors

  • Leyden, J; Pavlakis, N; Chan, D; Michael, M; Clarke, S; Khasraw, M; Price, T

Published Date

  • June 2018

Published In

Volume / Issue

  • 14 / 3

Start / End Page

  • 256 - 263

PubMed ID

  • 29105989

Pubmed Central ID

  • 29105989

Electronic International Standard Serial Number (EISSN)

  • 1743-7563

Digital Object Identifier (DOI)

  • 10.1111/ajco.12785

Language

  • eng

Conference Location

  • Australia